Evaluating the Effect of Standard-of-care Erythropoiesis-stimulating Agents on Forearm Blood Flow in Nondialysis-dependent Subjects With Anaemia Associated With Chronic Kidney Disease.

NCT ID: NCT02987465

Last Updated: 2024-02-07

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 29 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2017-02-20
• Study Completion Date: 2018-05-21

Brief Summary

In people diagnosed with chronic kidney disease (CKD) anaemia is a common problem and is often treated with EPO (Erythropoietin). One form of EPO used is Darbepoetin (Aranesp®). EPO is safe to use but it has been associated with a rise in blood pressure (BP) in some individuals. The reasons for this are not clear. To try to explain this, this study will look at how EPO affects certain substances in the blood that influence how blood vessels contract and relax. This will be conducted by infusing small amounts of Acetylcholine, BQ123 and Noradrenaline into the arm vessels of volunteers using an established method called Forearm blood flow (plethysmography). Volunteers recruited for this study will include CKD patients undergoing therapy with Darbepoetin as part of their normal NHS care as well as healthy people not on treatment, who will act as controls. This is an observational pilot study of changes in physiology before and after Darbepoetin. It will provide valuable data for a later study comparing Darbepoetin to novel agents which work via different pathways to treat anaemia.

Detailed Description

This is a pilot proposal to understand the changes in physiology in patients undergoing scheduled therapy with Darbepoetin as part of their normal NHS care. It is therefore an observational pilot study of changes in physiology before and after Darbepoetin. Conventional erythropoiesis stimulating agents (ESAs) are widely used to improve haemoglobin production and reduce anaemia in subjects with chronic kidney disease (CKD). However, ESAs are associated with the development of hypertension and increased cardiovascular morbidity and mortality. A number of potential underlying pathophysiological mechanisms have been postulated, mostly concerning around altered sensitivity to, or circulating levels of, endogenous vasoactive mediators. However, the existing data are inconsistent. Hand et al. found that short-term therapy with recombinant erythropoietin was associated with a rise in blood pressure, and an increase in vasoconstrictor responsiveness to infused noradrenaline, but not to endothelin-1. Serum endothelin-1 levels were elevated compared to controls at baseline, but did not change after erythropoietin therapy. Other groups have reported that ESA administration increases plasma levels of endothelin-1, and that this is strongly correlated with the increase in mean arterial pressure (MAP). Human endothelial cells incubated in ESAs show decreased eNOS expression and endothelial nitric oxide (NO) production. Ex-vivo studies in resistance vessels of subjects with CKD found impaired endothelial function, as assessed by acetylcholine mediated vasodilatation, which was partially reversed by blockade of the endothelin receptor (ET-A). In vivo acute and chronic ESA administration also impairs endothelial function, which is often considered as a surrogate of nitric oxide bioavailability.

Recently, newer agents have been postulated as a novel alternative to ESAs for treating renal anaemia. However, cardiovascular effects are incompletely characterised. Studies elucidating the mechanisms for ESA induced vasoconstriction and possible effects that promote cardiovascular disease are necessary and it would be imperative to study whether the use of these novel agents avoids these effects, potentially making them a better alternative to ESAs.

This pilot study aims to determine the putative mechanisms which may be involved in the BP response to ESA use in patients with anaemia associated with CKD who are EPO naïve within the last 12 months. Information gained from this study will inform a larger clinical trial that is being planned. Healthy volunteers will be recruited to provide a baseline of normal responses to compare against.

Conditions

Cardiovascular Diseases; Chronic Kidney Disease

Study Design

• Observational Model Type: CASE_CONTROL
• Study Time Perspective: PROSPECTIVE

Study Groups

Chronic Kidney Disease patients

Up to 12 patients with anaemia associated with CKD.

Darbepoetin Alfa

Intervention Type: DRUG

Darbepoetin is not a study drug and is prescribed as part of routine treatment of anaemia in CKD1. Darbepoetin is licensed for use for the treatment of anaemia in the context of CKD. It will be provided as part of the standard clinical care of the renal patients in this study. Healthy Volunteers will not be treated with Darbepoetin.

Acetylcholine

Intervention Type: DRUG

Acetylcholine is being used as a challenge agent in this study and assesses NO-mediated vasodilation

Noradrenaline

Intervention Type: DRUG

Noradrenaline is being used as a challenge agent in this study and is an endogenous a1 adrenoceptor agonist

BQ 123

Intervention Type: DRUG

BQ 123 is being used as a challenge agent in this study and is an (Endothelin A) ETA receptor agonist.

Healthy Volunteers

Up to 12 healthy subjects will be recruited such that age and gender are similar to the CKD patients. These subjects will be recruited as negative controls for a baseline assessment of healthy physiology. These subjects will not be treated with Darbepoetin.

Acetylcholine

Intervention Type: DRUG

Acetylcholine is being used as a challenge agent in this study and assesses NO-mediated vasodilation

Noradrenaline

Intervention Type: DRUG

Noradrenaline is being used as a challenge agent in this study and is an endogenous a1 adrenoceptor agonist

BQ 123

Intervention Type: DRUG

BQ 123 is being used as a challenge agent in this study and is an (Endothelin A) ETA receptor agonist.

Interventions

Darbepoetin Alfa

Darbepoetin is not a study drug and is prescribed as part of routine treatment of anaemia in CKD1. Darbepoetin is licensed for use for the treatment of anaemia in the context of CKD. It will be provided as part of the standard clinical care of the renal patients in this study. Healthy Volunteers will not be treated with Darbepoetin.

Intervention Type: DRUG

Acetylcholine

Acetylcholine is being used as a challenge agent in this study and assesses NO-mediated vasodilation

Intervention Type: DRUG

Noradrenaline

Noradrenaline is being used as a challenge agent in this study and is an endogenous a1 adrenoceptor agonist

Intervention Type: DRUG

BQ 123

BQ 123 is being used as a challenge agent in this study and is an (Endothelin A) ETA receptor agonist.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Provided written informed consent to participate
• Be aged 18 years or over
• Clinically suitable for EPO (Darbepoetin) therapy as part of routine NHS standard of care for anaemia due to chronic kidney disease (CKD)
• No prior EPO treatment within the preceding 12 months
• Palpable brachial artery

• Provided written informed consent to participate
• Aged 18 years or over
• Blood pressure <140/90
• Normal haematology and renal function (defined as a normal creatinine and eGFR measured at any time in the last 6 months or at screening)
• Not on any regular prescribed medication
• Palpable brachial artery

Exclusion Criteria

• Kidney transplant: Planned living-related kidney transplant within 26 weeks
• Patients on PDE5 inhibitors, alpha blockers, or nitrates (other than PRN GTN), unless they can be omitted until after the forearm study on the day of the visit
• MI or acute coronary syndrome in the preceding ≤ 4 weeks prior to screening
• Stroke or transient ischemic attack in the preceding ≤ 4 weeks prior to screening
• Known clinical diagnosis of Heart failure: NYHA Class III-IV heart failure, as defined by the New York Heart Association (NYHA) functional classification system.
• Clinic Blood pressure: sustained BP > 170/100 mm Hg (on repeated measurements)
• Pregnancy - Non-sterilised, pre-menopausal women will undergo urinary beta-HCG testing at every visit and be given advice on contraceptive use in the PIS.
• Any other reason for exclusion from this study in the opinion of the Principal Investigator

• Any condition which, in the opinion of the investigator, precludes enrolment
• Undergoing investigation for any serious medical condition

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

GlaxoSmithKline

INDUSTRY

Sponsor Role: collaborator

Cambridge University Hospitals NHS Foundation Trust

OTHER

Sponsor Role: lead

Responsible Party

Joseph Cheriyan, MD

Consultant Physician & Clinical Pharmacologist/Assoc Lecturer

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Joseph Cheriyan, MBCHB, MA, FRCP

Role: PRINCIPAL_INVESTIGATOR

Cambridge University Hospitals NHS Foundation Trust

Locations

Addenbrooke's Hospital

Cambridge, Cambridgeshire, United Kingdom

Countries

United Kingdom

Other Identifiers

OPERA-CKD (AO94224)

Identifier Type: -

Identifier Source: org_study_id